LEADER 02515nam 2200577Ia 450 001 9910449675803321 005 20200520144314.0 010 $a1-280-51529-5 010 $a9786610515295 010 $a1-84544-388-8 035 $a(CKB)1000000000018249 035 $a(EBL)289893 035 $a(OCoLC)133162020 035 $a(SSID)ssj0000475688 035 $a(PQKBManifestationID)11304153 035 $a(PQKBTitleCode)TC0000475688 035 $a(PQKBWorkID)10468944 035 $a(PQKB)10269931 035 $a(MiAaPQ)EBC289893 035 $a(Au-PeEL)EBL289893 035 $a(CaPaEBR)ebr10069021 035 $a(CaONFJC)MIL51529 035 $a(EXLCZ)991000000000018249 100 $a20000815d2004 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe workplace as a learning environment$b[electronic resource] /$fGuest editor David Moore 210 $aBradford, England $cEmerald Group Publishing$dc2004 215 $a1 online resource (61 p.) 225 0 $aThe journal of workplace learning ;$vv. 16, no. 6 300 $aDescription based upon print version of record. 311 $a0-86176-998-8 327 $aCONTENTS; Abstracts; Editorial; Guest editorial; Workplace participatory practices; Curriculum at work; The workplace learning cycle; Communities of domination? Reconceptualising organisational learning and power; Internet editorial 330 $aArguing against a concept of learning as only a formal process occurring in explicitly educational settings like schools, the paper proposes a conception of the workplace as a learning environment focusing on the interaction between the affordances and constraints of the social setting, on the one hand, and the agency and biography of the individual participant, on the other. Workplaces impose certain expectations and norms in the interest of their own continuity and survival, and in the interest of certain participants; but learners also choose to act in certain ways dependent on their own 606 $aEmployees$xTraining of 606 $aOrganizational behavior 608 $aElectronic books. 615 0$aEmployees$xTraining of. 615 0$aOrganizational behavior. 676 $a331.133 701 $aMoore$b David$0496164 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910449675803321 996 $aThe workplace as a learning environment$92205492 997 $aUNINA LEADER 04137nam 2200673Ia 450 001 9910957747303321 005 20251017110125.0 010 $a0-309-14733-6 010 $a1-282-43722-4 010 $a9786612437229 010 $a0-309-13815-9 035 $a(CKB)2670000000015886 035 $a(EBL)3378554 035 $a(SSID)ssj0000334899 035 $a(PQKBManifestationID)11285688 035 $a(PQKBTitleCode)TC0000334899 035 $a(PQKBWorkID)10271951 035 $a(PQKB)11315380 035 $a(MiAaPQ)EBC3378554 035 $a(Au-PeEL)EBL3378554 035 $a(CaPaEBR)ebr10355552 035 $a(CaONFJC)MIL243722 035 $a(OCoLC)923281077 035 $a(DNLM)1523856 035 $a(BIP)53855706 035 $a(BIP)28187512 035 $a(EXLCZ)992670000000015886 100 $a20091202d2009 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAssessing and improving value in cancer care $eworkshop summary /$fAdam Schickedanz, rapporteur ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$dc2009 215 $a1 online resource (165 p.) 300 $aDescription based upon print version of record. 311 08$a0-309-13814-0 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Preface""; ""1 Introduction""; ""2 Opening Remarks: What Is Value in Cancer Care and Why Is It Important?""; ""PART I: Challenges to Value in Cancer Care""; ""3 Clinician Patient Communication and Its Influence on Value""; ""4 Generating Evidence About Effectiveness and Value""; ""5 Value and the Oncology Market""; ""6 Value in Oncology Practice: Oncologist and Health Insurer Perspectives""; ""7 Ethical Issues and Value in Oncology""; ""PART II:Solutions for Value in Cancer Care""; ""8 Improving Value in Oncology Practice: Ways Forward"" 327 $a""9 Toward a Shared Understanding of Value""""Acronyms""; ""Glossary""; ""Appendix A: Workshop Agenda""; ""Appendix B: Speaker and Moderator Biographies"" 330 $aUnlike many other areas in health care, the practice of oncology presents unique challenges that make assessing and improving value especially complex. First, patients and professionals feel a well-justified sense of urgency to treat for cure, and if cure is not possible, to extend life and reduce the burden of disease. Second, treatments are often both life sparing and highly toxic. Third, distinctive payment structures for cancer medicines are intertwined with practice. Fourth, providers often face tremendous pressure to apply the newest technologies to patients who fail to respond to established treatments, even when the evidence supporting those technologies is incomplete or uncertain, and providers may be reluctant to stop toxic treatments and move to palliation, even at the end of life. Finally, the newest and most novel treatments in oncology are among the most costly in medicine. This volume summarizes the results of a workshop that addressed these issues from multiple perspectives, including those of patients and patient advocates, providers, insurers, health care researchers, federal agencies, and industry. Its broad goal was to describe value in oncology in a complete and nuanced way, to better inform decisions regarding developing, evaluating, prescribing, and paying for cancer therapeutics. 606 $aCancer$xPatients$xMedical care 606 $aCancer$xTreatment$xEconomic aspects 606 $aCancer 615 0$aCancer$xPatients$xMedical care. 615 0$aCancer$xTreatment$xEconomic aspects. 615 0$aCancer. 676 $a616.994 701 $aSchickedanz$b Adam$01851692 712 02$aNational Cancer Policy Forum (U.S.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910957747303321 996 $aAssessing and improving value in cancer care$94445914 997 $aUNINA